Diagnostic Approach for Urinary Retention Suspected Due to BPH

Initial Assessment

• The American Urological Association recommends administering the International Prostate Symptom Score (IPSS) questionnaire to objectively quantify both obstructive symptoms and irritative symptoms 2, 4
• A detailed medical history should be obtained, focusing on duration and progression of urinary symptoms, and previous episodes of urinary retention or BPH-related complications 1, 4

Physical Examination

• A digital rectal examination (DRE) should be performed to assess prostate size and consistency, and presence of nodules that might suggest prostate cancer rather than BPH 1

Essential Diagnostic Tests

• Urinalysis should be performed to exclude urinary tract infection, hematuria, or other inflammatory conditions 1, 3
• Serum PSA measurement is recommended in patients with at least a 10-year life expectancy or when knowledge of prostate cancer would change management 1, 3
• Measurement of post-void residual (PVR) urine volume can be performed using bladder ultrasound or catheterization 5

Additional Diagnostic Evaluations

• Uroflowmetry can be used to measure maximum urinary flow rate (Qmax), with Qmax <10 mL/sec suggesting urodynamic obstruction 5

Management of Acute Urinary Retention

• Immediate bladder decompression via catheterization is essential, and administration of an alpha blocker prior to catheter removal increases the chance of successful voiding trial 6, 7

Follow-Up Protocol

• The first follow-up visit should be scheduled 4-12 weeks after initiating alpha blockers, and IPSS should be readministered at each follow-up visit to objectively assess symptom changes 3

Common Pitfalls to Avoid

• Failing to consider prostate size when evaluating treatment response, and neglecting to assess for complications of BPH that may require more urgent intervention 3, 1, 6
• Surgical intervention is recommended for patients with renal insufficiency due to BPH, recurrent UTIs, recurrent gross hematuria, or bladder stones due to BPH that are refractory to other therapies 6, 8